S
Sense Biodetection
Health Tech & Medtech · Clifton Hampden, United Kingdom · Founded 2014
Instrument-free, rapid, point-of-care molecular diagnostic tests MoreLess
Sense Biodetection, founded in 2014 by Harry and Ralph Lamble, was a global molecular diagnostics company that developed instrument-free, point-of-care tests. In February 2023, the company was acquired by Sherlock Biosciences for undisclosed terms. The acquisition was aimed at accelerating Sherlock's market strategy by integrating Sense's Veros™ platform and manufacturing capabilities.
The company was headquartered in Abingdon, United Kingdom, with additional operations in Cambridge, UK, and Milford, Massachusetts, USA. Sense focused on developing disposable molecular diagnostic tests that provided laboratory-quality results without the need for a reader or external power. Its proprietary Veros™ product platform utilized rapid molecular amplification technology to detect various diseases. The first product launched on this platform was the Veros™ COVID-19 test, which received a CE Mark in March 2022, allowing it to be sold in the European Union. This test could deliver PCR-quality results from a nasal swab in under 15 minutes.
The company's business model centered on providing accessible and affordable diagnostic solutions to improve patient outcomes and lower healthcare costs by enabling testing in various settings beyond traditional laboratories. Sense had secured a total of $79.2 million in funding over six rounds from investors including Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health. The acquisition by Sherlock Biosciences combines Sense's hardware and chemistry with Sherlock's CRISPR-based technologies to advance the development of handheld, highly accurate tests for a range of health issues, including respiratory and sexual health.
Keywords: molecular diagnostics, point-of-care testing, instrument-free diagnostics, rapid diagnostic tests, Veros platform, COVID-19 test, healthcare technology, medical devices, disposable diagnostics, nucleic acid amplification, decentralized testing, CE Mark, infectious disease testing, Sherlock Biosciences acquisition, diagnostic technology, biotechnology
Company overview
Sense Biodetection company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Clifton Hampden, United Kingdom
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 67.2
Valuation & funding
Sense Biodetection funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2023 | $0 | — | Sherlock Biosciences | ↗ |
| SERIES BOther financing | Nov 2021 | $15M | $250M | Koch Disruptive Technologies | ↗ |
| SERIES BOther financing | Apr 2021 | $50M | $200M | Earlybird Venture Capital · Mercia Asset Management · Jonathan Milner · Cambridge Innovation Capital | — |
| GRANTOther financing | Oct 2019 | $2.4M | — | Undisclosed | — |
| SERIES AOther financing | Oct 2019 | $16M | $65M | Mercia Asset Management · Jonathan Milner · Earlybird Venture Capital · Cambridge Innovation Capital | ↗ |
| GRANTOther financing | Apr 2019 | Undisclosed | — | ||
| SEEDOther financing | Jul 2016 | Angels in MedCity · Mercia Asset Management | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $15K | 0% | −$39M | -256898.8% |
| 2025 | $15K | 0% | −$39M | -256898.8% |
| 2024 | $15K | 0% | −$39M | -256898.8% |
| 2023 | $15K | 0% | −$39M | -256898.8% |
| 2022 | $15K | -98.7% | −$39M | -256898.8% |
| 2021 | $1.2M | -58.9% | −$11M | -938.7% |
| 2020 | $2.9M | — | −$731K | -25.3% |
Growth signals
Sense Biodetection website traffic
Latest recorded traffic for Sense Biodetection is 430 monthly website visits, down 87.4% over the last three months. Sense Biodetection's team declined 27.3% over the past year.
Comparisons
Sense Biodetection compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Sense Biodetection's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Sense Biodetection has talent and traffic
team presence
In the news
Latest news about Sense Biodetection
Recent press, funding announcements, and product moves mentioning Sense Biodetection — open to read from the original sources.
Market sentiment
What the market is saying about Sense Biodetection
An AI-synthesized read of the highest-engagement posts about Sense Biodetection on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sense Biodetection’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.